Evidence map›Paper›PMID 34469011›Full record

ArticleDrug development research2021

Disruption of the biological activity of protease-activated receptors2/4 in adults rather than children in SARS CoV-2 virus-mediated mortality in COVID-19 infection.

Yogendra Singh, Neeraj Kumar Fuloria, Shivkanya Fuloria, Vetriselvan Subramaniyan, Waleed Hassan Almalki, Gaurav Gupta, Mohammad Arshad Javed Shaikh, Mahaveer Singh, Fahad A Al-Abbasi, Imran Kazmi

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug development research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Cancer management during the COVID-19 world pandemic.Cancer immunology, immunotherapy : CII · 2023
    Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

Yogendra SinghDepartment of Pharmacology, Maharishi Arvind College of Pharmacy, Ambabari, Jaipur, India.ORCID 0000-0001-6132-5106
Neeraj Kumar FuloriaDepartment of Pharmacy I Centre of Excellence for Biomaterials Engineering, AIMST University, Bedong, Kedah, Malaysia.
Shivkanya FuloriaDepartment of Pharmacy I Centre of Excellence for Biomaterials Engineering, AIMST University, Bedong, Kedah, Malaysia.
Vetriselvan SubramaniyanDepartment of Medicine, Bioscience and Nursing, MAHSA University, Jalan SP 2, Bandar Saujana Putra, Jenjarom Selangor, Malaysia.
Waleed Hassan AlmalkiDepartment of Pharmacology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Gaurav GuptaDepartment of Pharmacology, School of Pharmacy, Suresh Gyan Vihar University, Jaipur, India.
Mohammad Arshad Javed ShaikhDepartment of Pharmacology, School of Pharmacy, Suresh Gyan Vihar University, Jaipur, India.
Mahaveer SinghSchool of Pharmaceutical Sciences, Jaipur National University, Jaipur, India.
Fahad A Al-AbbasiDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Imran KazmiDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID 0000-0002-6272-1976
AIMST University · MYGyan Vihar University · INKing Abdulaziz University · SAJaipur National University · INMaharishi Markandeshwar University, Mullana · INMahsa University · MYUmm al-Qura University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the most remarkable results in 2019 is the reduced prevalence and death of children from coronavirus infection (COVID-19). In 2019, a worldwide pandemic impacted around 0.1 billion individuals, with over 3.5 million mortality reported in the literature. There is minimal knowledge on SARS-CoV-2 infection immunological responses in kids. Studies have been focused mostly on adults and children since the course of pediatric sickness is often short. In adults, severe COVID-19 is related to an excessive inflammatory reaction. Macrophages and monocytes are well known to contribute to this systemic response, although numerous lines are indicative of the importance of neutrophils. An increased number of neutrophils and neutrophil to lymphocyte ratios are early signs of SARS-CoV-2 and a worse prognosis. In this study that it is crucial to monitor PAR2 and PAR4 expression and function (since nursing children have elevated levels) and the inhibiting the normal physiology through the use of anticoagulants may exacerbate the problem in adults. Thus, in COVID-19 infection, we propose the use of antiplatelet (thromboxane A2 inhibitors), if required rather than anticoagulants (FXa and thrombin Inhibitors).

Indexed as

AdultAge FactorsAnticoagulantsChildCOVID-19COVID-19 Drug TreatmentHumansLymphocyte CountNeutrophilsPlatelet Aggregation InhibitorsReceptor, PAR-2Receptors, ThrombinAnticoagulantsF2RL1 protein, humanPlatelet Aggregation Inhibitorsprotease-activated receptor 4Receptor, PAR-2Receptors, ThrombinantiplateletCOVID-19SARS CoV-2

Identifiers

PMID34469011
PMCPMC8653207
OpenAlexW3196345780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.